Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group

Rebbeck, Timothy R.; Friebel, Tara M.; Wagner, Theresa; Lynch, Henry T.; Garber, Judy E.; Daly, Mary B.; Isaacs, Claudine; Olopade, Olufunmilayo I.; Neuhausen, Susan L.; Veer, Laura van ‘t; Eeles, Rosalind; Evans, D. Gareth; Tomlinson, Gail E.; Matloff, Ellen; Narod, Steven A.; Eisen, Andrea; Domchek, Susan M.; Armstrong, Katrina; Weber, Barbara

doi:10.1200/jco.2004.00.8151

Cited by 384 publications

(247 citation statements)

References 27 publications

Supporting

Mentioning

224

Contrasting

Unclassified

Order By: Relevance

“…In the only study published to date, Rebbeck et al (2005) reported that the protective effect offered by oophorectomy was not attenuated by the prescription of HRT. Compared to women who did not have an oophorectomy, the combination of HRT and oophorectomy was associated with a significant reduction in breast cancer risk (hazard ratio ¼ 0.37, 95% CI: 0.14-0.96).…”

Section: Hormone Replacement Therapymentioning

confidence: 98%

Modifiers of risk of hereditary breast cancer

Narod

2006

Oncogene

View full text Add to dashboard Cite

Mutations in the BRCA1 and BRCA2 genes confer a high lifetime risk of breast and ovarian cancer. The risk varies from individual to individual, and it appears that the risk has increased in recent generations. These observations imply that non-genetic factors may modify the inherited risk. To date, the factors that appear most strongly to modify the risk include reproductive histories and exogenous hormones. Oral contraceptives are associated with a profound reduction in the risk of ovarian cancer, and with little or no increase in the risk of breast cancer. Other modifying factors include age of menarche, parity, breastfeeding and oophorectomy. The effect of parity is different in BRCA1 and BRCA2 carriers. Multiparity appears to be protective in BRCA1 carriers, but is associated with an increase in risk in BRCA2 carriers. Oophorectomy has been associated with reductions in both the risk of breast and ovarian cancer. Knowledge of these risk factors will be useful for managing risk and for developing prevention strategies.

show abstract

Section: Hormone Replacement Therapymentioning

confidence: 98%

Modifiers of risk of hereditary breast cancer

Narod

2006

Oncogene

View full text Add to dashboard Cite

show abstract

“…Low-dose hormone replacement therapy (HRT) does not appear to decrease the preventive effect of SO on the BC risk. 44 In women younger than 50 years of age with no history of BC, HRT may be prescribed 45 in the presence of severe menopausal symptoms. The age at which SO should be recommended is still a subject of controversy, particularly in BRCA2 carriers.…”

Section: Discussionmentioning

confidence: 99%

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Laki

Kirova

This

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.Prophylactic salpingo‐oophorectomy (SO), which is recommended in BRCA1/2 mutation carriers, still needs to be reappraised.METHODS.In all, 89 BRCA1/BRCA2 mutation carriers underwent SO between 1994–2004. Past medical and familial history, SO, results and survival after SO were analyzed.RESULTS.The series consisted of 56 BRCA1 and 33 BRCA2 mutation carriers. All but 1 had a family history of breast (BC) and/or ovarian cancer; 42 BRCA1 and 31 BRCA2 had a personal history of BC. The median age at SO was 44 (BRCA1) and 49.5 (BRCA2) years for women without previous BC (not significant) and 48 (BRCA1) and 53 BRCA2) years (P = .03) for women with previous BC. Occult ovarian (n = 2) and/or fallopian (n = 3) carcinomas were found in 4 patients (4.5%): 1 experienced recurrence (4 years), 2 are disease‐free (26 and 38 months of follow‐up), and 1 died from BC (12 months). Among the other 69 patients with previous BC (median follow‐up, 42 months), 14 developed ipsilateral or contralateral BC and 8 developed metastatic disease. Among the 16 patients without previous BC (median follow‐up, 27 months), 3 developed BC. Of the 89 patients, 85 are still alive: 3 died from BC and 1 died from pancreatic cancer. No peritoneal malignancy was observed.CONCLUSIONS.This study shows that prophylactic SO remains an important option for BRCA1/2 mutation carriers as asymptomatic ovarian/fallopian cancers were found in 4.5% of patients. However, a longer follow‐up and larger series are required to more precisely evaluate the benefits of this procedure in terms of BC incidence, peritoneal malignancy, or recurrence. Cancer 2007. © 2007 American Cancer Society.

show abstract

“…To reduce the mortality of ovarian cancer, BRCA1/2 mutation carriers are currently being counselled for gynaecological screening and prophylactic bilateral (salpingo-) oophorectomy (BP(S)O). Although efficacy of BPSO has been demonstrated (Rebbeck et al, 2005), the efficacy of gynaecological screening with (bi) annual transvaginal ultrasonography (TVU) and the serum tumour marker CA125 (Karlan et al, 1993;Burke et al, 1997) is still unclear. To summarize the literature on gynaecological screening of BRCA1/2 carriers, including overlap with the present study, eight interval cancers among 24 cancers were diagnosed among a total of 807 BRCA1/2 carriers (Table 1) (Laframboise et al, 2002;Liede et al, 2002;Scheuer et al, 2002;Fries et al, 2004;Kauff et al, 2005;Meeuwissen et al, 2005;Vasen et al, 2005;Gaarenstroom et al, 2006;Oei et al, 2006).…”

mentioning

confidence: 99%

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

et al. 2007

View full text Add to dashboard Cite

BRCA1/2 mutation carriers are offered gynaecological screening with the intention to reduce mortality by detecting ovarian cancer at an early stage. We examined compliance and efficacy of gynaecological screening in BRCA1/2 mutation carriers. In this multicentre, observational, follow-up study we examined medical record data of a consecutive series of 888 BRCA1/2 mutation carriers who started annual screening with transvaginal ultrasonography and serum CA125 between 1993 and 2005. The women were annually screened for 75% of their total period of follow-up. Compliance decreased with longer follow-up. Five of the 10 incident cancers were interval tumours, diagnosed in women with a normal screening result within 3–10 months before diagnosis. No difference in stage distribution between incident screen-detected and interval tumours was found. Eight of the 10 incident cancers were stage III/IV (80%). Cancers diagnosed in unscreened family members had a similar stage distribution (77% in stage III/IV). The observed number of cases detected during screening was not significantly higher than expected (Standardized Incidence Ratio (SIR): 1.5, 95% confidence interval: 0.7–2.8). For the subgroup that was fully compliant to annual screening, a similar SIR was found (1.6, 95% confidence interval: 0.5–3.6). Despite annual gynaecological screening, a high proportion of ovarian cancers in BRCA1/2 carriers are interval cancers and the large majority of all cancers are diagnosed in advanced stages. Therefore, it is unlikely that annual screening will reduce mortality from ovarian cancer in BRCA1/2 mutation carriers.

show abstract

Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group

Abstract: Short-term HRT use does not negate the protective effect of BPO on subsequent breast cancer risk in BRCA1/2 mutation carriers.

Cited by 384 publications

References 27 publications

Modifiers of risk of hereditary breast cancer

Modifiers of risk of hereditary breast cancer

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study

Contact Info

Product

Resources

About